Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2025 value amounting to $310.0 million.

  • Agios Pharmaceuticals' Long-Term Investments fell 5143.31% to $310.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $310.0 million, marking a year-over-year decrease of 5143.31%. This contributed to the annual value of $310.0 million for FY2025, which is 5143.31% down from last year.
  • According to the latest figures from Q4 2025, Agios Pharmaceuticals' Long-Term Investments is $310.0 million, which was down 5143.31% from $304.3 million recorded in Q3 2025.
  • Agios Pharmaceuticals' 5-year Long-Term Investments high stood at $655.9 million for Q3 2024, and its period low was $21.6 million during Q1 2021.
  • Over the past 5 years, Agios Pharmaceuticals' median Long-Term Investments value was $269.1 million (recorded in 2021), while the average stood at $271.5 million.
  • In the last 5 years, Agios Pharmaceuticals' Long-Term Investments tumbled by 9062.2% in 2023 and then soared by 206857.82% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Long-Term Investments (Quarter) stood at $266.4 million in 2021, then grew by 17.83% to $313.9 million in 2022, then crashed by 90.62% to $29.4 million in 2023, then surged by 2068.58% to $638.3 million in 2024, then tumbled by 51.43% to $310.0 million in 2025.
  • Its Long-Term Investments stands at $310.0 million for Q4 2025, versus $304.3 million for Q3 2025 and $400.5 million for Q2 2025.